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The Biopharmaceutics Classification System (BCS) for oral immediate release solid drug 
products have been very successful; its implementation in drug industry and regulatory approval 10 
has shown significant progress.  This has been the case primarily because BCS was developed 
using sound scientific judgment.  Following the success of BCS, we have considered the topical 
drug products for similar classification system based on sound scientific principles.  
In USA, most of the generic topical drug products have qualitatively (Q1) and 
quantitatively (Q2) same excipients as the reference listed drug (RLD). The applications of in 15 
vitro release (IVR) and in vitro characterization are considered for a range of dosage forms 
(suspensions, creams, ointments and gels) of differing strengths. We advance a Topical Drug 
Classification System (TCS) based on a consideration of Q1, Q2 as well as the arrangement of 
matter and structure of topical formulations (Q3). Four distinct classes are presented for the 
various scenarios that may arise and depending on whether biowaiver can be granted or not.  20 
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Topical dermatological products are liquid or semisolid preparations such as creams, 25 
ointments, lotions and gels. They deliver drugs to various layers of the skin to prevent or treat 
diseases. The onset, duration and magnitude of therapeutic response for any topical 
formulation depends on the relative efficiency of three sequential processes: release of the 
active drug substance from the dosage form (drug release), penetration/diffusion of the drug 
through the stratum corneum and other layers of skin before eliciting the desired 30 
pharmacological effect at the site of action. These processes are variable which results in 
differences in the safety and efficacy of the formulation. Ultimately such variability results in 
serious challenges in the determination of bioequivalence (BE) of topical dermatologic 
products, challenges which encumber the development of acceptable generic formulations by 
the pharmaceutical industry and their approval by regulatory authorities. 35 
In the US a generic product is required to be both pharmaceutically equivalent (PE) and 
BE. PE means that the generic product has the same active ingredient in the same amount and 
same type of dosage form.  In addition, according to 21 CFR 314.94 for topical dosage forms 
(2013), the generic product will need to have the same excipients and be qualitatively (Q1) and 
quantitatively (Q2) the same as the RLD. When a generic product is approved it is considered 40 
therapeutically equivalent and interchangeable with the brand name product. BE of a topical 
dosage form is documented by comparing the test and reference products using 
pharmacokinetic, pharmacodynamic, clinical or in vitro tests. Currently, comparative clinical 
endpoint trials are used to establish BE for most dermatological drug products except for 
glucocorticoids which are tested via an established pharmacodynamic test (US-FDA, 1997). 45 
Clinical trials require the demonstration of BE of the generic drug to the RLD, using one or more 
clinical endpoints and assuring efficacy by establishing superiority of the generic formulation 
and RLD over placebo. These trials with vigorous statistical requirements are associated with a 
high degree of variability and low sensitivity to formulation factors which means that they are 
comparatively less efficient and in some cases not conclusive. In order to meet a minimum 50 
statistical power to show efficacy and BE of a generic product and RLD reliably, a clinical trial 
with enrollment of a large number of patients will be needed. Such trials are often tedious, 
expensive and sometimes impossible to complete. Because of these reasons, it can be 
3 
 
concluded that in many cases the regulatory requirements for generic topical drug products are 
complex, cumbersome, and time consuming.  55 
The FDA has recently issued two draft guidances for generic acyclovir ointment (US-FDA, 
2012) and cyclosporine ophthalmic emulsion (US-FDA, 2013) including an in vitro option to 
establish BE, provided a set of qualification criteria are met. This development is viewed with 
optimism by the authors to offer the opportunity for new initiatives, relying on comparative 
physico-chemical evaluation of topical semisolids and in vitro release (IVR) testing.  60 
During a recent BE workshop on Current challenges in bioequivalence, quality, and novel 
assessment technologies for topical products (Yacobi et al., 2014), opportunities to simplify the 
regulatory requirements have been identified. Considering the science developed for Scale Up 
and Post Approval Changes for nonsterile Semisolid Dosage Forms (SUPAC-SS, 1997) and the 
principles of IVR, a biowaiver based on rigorous in vitro characterization of the dosage form 65 
compared with the RLD is feasible (US-FDA, 2012; 2013). The draft guidelines of acyclovir 
ointment and cysclosporin ophthalmic emulsion are an extension of SUPAC-SS guidance based 
on well-established and time honored scientific principles. More importantly, there is no 
evidence suggesting that the application of approaches identified in SUPAC-SS compromise the 
quality of topical dosage forms. The IVR is recognized as the most important test to assure the 70 
quality of the drug product. Herein we enunciate practical applications of science based 
principles of SUPAC-SS combined with the use of IVR methods for regulatory evaluation of 
topical drug products and propose the concept of developing a relevant “Topical Drug 
Classification System (TCS)” which may be used by both the pharmaceutical industry and 
regulatory agencies across the world. 75 
 
2. IN VITRO DRUG RELEASE 
The efficacy of a topically applied dosage form may be dependent on drug release, 
therefore the IVR rate (profile) theoretically constitutes an important and valuable product 
quality parameter. The development of simple, reliable, reproducible and validated methods to 80 
determine the drug release from a semisolid dosage form using a vertical diffusion cell (VDC) 
system and a synthetic membrane was reported (Shah et al., 2003; Hauck et al., 2007). The 
4 
 
authors’ preference is to use VDC for IVR determination, because of long experience and 
adequate standardization with this apparatus. However, other methods are also described 
(USP37-NF32, 2014). 85 
  
3. SCALE UP AND POST APPROVAL CHANGES (SUPAC-SS) 
The topical semisolid drug products are complex formulations with complex structural 
configurations. The API is either dissolved or dispersed in the vehicle. The physical properties of 
the dosage form are dependent on various factors, including the size of the dispersed particles, 90 
arrangement and interactions between the dispersed materials, the particle size of the API, the 
interfacial tension between the phases, the partition coefficient of the drug between the 
phases, and the product rheology. 
The SUPAC-SS guidance (1997) was developed to address (i) changes in the component or 
composition (ii) changes in the manufacturing process and equipment (iii) the scale-up/scale-95 
down of manufacture, and/or change in site of manufacture of a semisolid formulation during 
the post-approval period. The Level 2 change can include: (i) changes of > 5 and ≤ 10% of 
excipients (ii) change in equipment to a different design or different operating principles; 
process changes including changes in rate of mixing, rate of cooling, operating speeds and 
holding time (iii) change in batch size beyond a factor of 10. 100 
 The IVR is recommended to assure that consistent product performance will be achieved 
after Level 2 changes. The IVR of the changed product must be the same as for the initially 
approved drug product. In this scenario, IVR is used as a measure of equivalence in product 
performance, and is used to requalify the initially approved product after an acceptable change. 
Thus, the IVR is considered to be a useful test to assess product sameness between pre-change 105 
and post-change product. Moreover, IVR test has also been recognized as a reasonable and 
useful test to consider for product release and stability testing (Chang et al., 2013). In vitro non-
similarity could be a signal of altered in vivo performance (SUPAC-SS, 1997; USP37-NF32, 2014). 
Direct confirmation of structural equivalency is difficult to obtain where a formulation is 
not a solution (Lionberger, 2004). Available reports suggest that Q1 and Q2 equivalent 110 
products, also bioequivalent as demonstrated by clinical endpoint studies, displayed Q3 
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difference (spreadability differences; Kryscio et al., 2008). Therefore, structural analysis alone 
cannot provide adequate information on the first step of the release process, the diffusion 
through the semisolid matrix. We consider feasible to rely on the use of simple, reliable and 
reproducible IVR methodology for the evaluation of Q3 similarity, i.e. the same state of 115 
aggregation and the same arrangement of the matter or microstructure. When adequately 
developed and validated, IVR methodology can provide information on the combined role of 
several physico-chemical characteristics, including the particle or droplet size, viscosity and 
diffusional resistance of the vehicle.  
After extensive research, Klein and coworkers (2010) confirmed the principles of SUPAC-120 
SS guidance (1997) and statements of the 1999 AAPS-FDA workshop report (Flynn et al., 1999). 
Pillai et al (2001) also confirmed that the IVR methodology is a feasible, reliable “product 
qualifying tool”, the release rates being sensitive indicators of the “state of solubilization of a 
drug, to the drug’s particle size, to the method and rigor of drug distribution, and to other 
factors of system composition and processing” (Flynn et al., 1999). 125 
 
4. WAIVER FOR LOWER STRENGTHS OF TOPICAL DOSAGE FORMS 
In the case of multi strength dosage forms of tablets and capsules, an in vivo BE study 
comparing the highest potency of test and RLD product is required. For the lower strengths a 
biowaiver is allowed, provided that the additional strengths are formulation proportional or 130 
pseudo-proportional for high potency drug, have the same drug releasing mechanism and have 
similar drug release profiles when compared to the highest strength of the bioequivalent 
product (US-FDA, 2003). Generally, different strengths of topical dosage forms from a given 
manufacturer differ only in the amount of active ingredient,  the basic formulation or vehicle is 
the same for all strengths. This general similarity between oral and topical dosage forms is 135 






As an example, assume that two strengths differ by 50%, i.e., they are 0.5% and 0.25%. 140 
The IVR for the lower strength will depend on the status of the active ingredient, either 
dissolved or dispersed; if it is in solution form, the IVR for the lower strength will be half that of 
the higher strength, and if it is in suspension form, the IVR for the lower strength will be 
proportional to the square root of 2 (Pillai et al., 2001). The IVR ratio for the two strengths will 
be equal to the ratio of the amount or concentration of the dissolved active pharmaceutical 145 
ingredient. In the case of the dispersed system, the IVR will be equal to the square root of the 
amount or concentration of the dissolved active pharmaceutical ingredient. These relationships 
provide a framework for allowing a biowaiver for lower strengths of the topical dosage form 
produced by the same manufacturer.  
 150 
5. BIOPHARMACEUTICS CLASSIFICATION SYSTEM (BCS) 
The Biopharmaceutics Classification System (BCS) for immediate release solid oral dosage 
form is based on the properties of the API, its aqueous solubility and intestinal permeability 
(US-FDA, 2000). This scientifically sound framework has gained wide regulatory acceptance and 
allows the use of  in vitro dissolution testing as alternative for in vivo BE studies, provided a set 155 
of clearly defined solubility, permeability and dissolution criteria are met. Generic immediate 
release dosage forms of the BCS class 1 and class 3 drugs are eligible for biowaiver, if 
dissolution criteria are met when compared to the RLD. The validity of the principles underlying 
the BCS classification has been confirmed based on its utilization in drug development in 
industry and its implementation in regulatory approval process.  BCS class 2 and 4 are not 160 
eligible for biowaiver and require in vivo BE studies. 
 
6. TOPICAL DRUG CLASSIFICATION SYSTEM (TCS) 
 
The proposed topical drug classification system is based on qualitative and quantitative 165 
equivalence of composition (Q1 and Q2) and on the similarity of IVR rates (as estimator of 
microstructural sameness, Q3) between two compared formulations, a generic product and 
RLD. The excipients in topical dosage forms can play an active role in the in vivo performance of 
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the formulations compared to immediate release oral dosage forms. Depending on the nature 
and quantity, the excipients may have a significant impact on the release from the dosage form, 170 
on the skin barrier properties and drug penetration, directly affecting rate and extent of 
exposure at site of action. The IVR (Q3) reflects the microstructure, arrangement of the matter 
and the state of aggregation of the dosage form. If all three parameters, Q1, Q2 and Q3 are the 
same between the RLD and the generic product, the generic product may be suitable for a 
biowaiver. If they are not the same, then of course, biowaiver cannot be provided and 175 
additional studies or a biostudy will be required. Using these scientific principles, a topical drug 
classification system (TCS) is proposed to simplify the regulatory requirements for topical 
dosage forms, and is shown in Figure 2.  
 
Figure 2. 180 
 
Based on composition and IVR similarity, the compared dosage forms are classified as TCS 
class 1, 2, 3 and 4. Under the proposed classification, only TCS class 1 and TCS class 3 dosage 
forms are eligible for biowaiver; TCS class 2 and TCS class 4, are not eligible for biowaiver and 
will require in vivo BE studies  for drug approval. The nature and type of in vivo BE study will 185 
depend on the therapeutic class and dosage form category. The proposed TCS is as follows: 
 If the product is Q1 and Q2, and if it meets IVR (Q3) comparison criteria and confidence 
intervals identified in SUPAC-SS, a biowaiver can be provided. This may be classified as 
TCS class 1 and corresponds to the definition of Level 1 changes in the SUPAC-SS 
guidance. There is no reason to expect the generic product to perform differently than 190 
the RLD under such a scenario. 
 If the product is Q1 and Q2, but has different Q3, then a biowaiver cannot be granted, 
and an appropriate BE study should be required. This may be classified as TCS class 2. 
 If the generic product is not Q1 and Q2, then it necessitates evaluation of the excipients, 
to determine if they are inert or not inert. Excipients can influence drug penetration and 195 
may have an effect on in vivo performance of the product, thereby changing the safety 
and efficacy profiles. It is therefore essential to evaluate the properties of the excipients 
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with respect to safety and efficacy, as well as how excipients affect both the 
thermodynamic activity of the active pharmaceutical ingredient and the skin 
permeability. In addition, the IVR needs to be determined. If the IVR turns out to be the 200 
same as the RLD, and meets the confidence interval criteria, then the dosage form can 
be provided with a biowaiver. This may be classified as TCS class 3. 
 If the generic product is not Q1 and Q2, and IVR is different, then biowaiver cannot be 
granted, and an appropriate in vivo study will be required for topical drug product 
approval. This may be classified as TCS class 4. 205 
 
7. DISCUSSION 
The BCS for solid oral dosage forms is based on sound scientific principles and has 
reduced regulatory burden and avoided unnecessary in vivo study requirements for a number 
of drug products. The BCS has been in place for over a decade and has resulted in considerable 210 
success in facilitating the development and approval of a larger number of generic products 
with considerable savings to the consumer.   These API products with high solubility and 
permeability characteristics are approved based on dissolution studies.    
Regulatory requirements for generic topical drug products are complex and cumbersome, 
time consuming and at times questionable as they prevent the possibility of developing 215 
alternative and more affordable products. Recently, the FDA has allowed the utilization of 
accepted and validated in vitro methods for generic approval of at least two products: acyclovir 
ointment and cyclosporine ophthalmic emulsion. Conducting reliable and successful clinical 
end-point bioequivalence studies for these products was near to impossible. However, the 
consideration of in vitro tests for topical products in lieu of clinical studies offered the 220 
opportunity to explore the application of such tests to other products which have been 
considered “untouchables” for development by generic firms. Therefore, the development of a 
science based approach to elucidate the requirements for the development of safe, effective 
and interchangeable topical generic drug products should play a key role to advance the 
approval of generic products which have enjoyed unintended protection from competition. The 225 
purpose of this communication is to offer possible use of an approach similar to the BCS that 
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may be referred to as the TCS system which is also based on established scientific principles  
specifically developed for semisolid topical products. Unlike the officially adopted BCS which is 
based on the solubility and permeability characteristics of the drug, the proposed TCS considers 
the qualitative and quantitative composition of inactive ingredients and microstructure 230 
arrangement of topical semisolid products.  In both the classification systems,  their 
applicability for biowaiver granting relies on the use of in vitro methodologies as key decision 
tools.   
The principles are in-line with the previous proposal of a decision tree, for drugs targeting 
the stratum corneum (Lionberger, 2004). If products were Q1 and Q2 equivalent, IVR testing 235 
was recommended, with in vivo testing waived based on the conclusion of similarity, this 
corresponds  to the present approach for TCS class 1. For products Q1 equivalent with Q2 
differences, IVR was suggested, supplemented by in vivo evaluations (defined as potential 
alteration of either skin permeability or solubility of drug in the formulation). In case of Q1 and 
Q2 non-equivalencies, IVR and in vivo approaches were to be required in order to demonstrate 240 
the lack of a formulation effect on absorption. 
The SUPAC-SS guidance which provides assurance for product sameness between 
approved and post-approval product, has been in place for almost two decades and is based on 
IVR principles. This criteria was expanded further with Q1 and Q2 criteria, with added Q3 
requirements, indicating that with Q1 and Q2 being the same, a generic product so 245 
manufactured falls into the category of SUPAC-SS Level 2 changes. If IVR (Q3) is the same, 
indicating a strong likelihood that the formulation process confers similar product structure, a 
biowaiver may be granted. Using the well-established BCS schematic, the TCS schematic is 
presented in Figure 3. If a similar system is considered, it will allow the use of already 
established and utilized methodologies which will significantly reduce the burden for generic 250 
topical drug product development and approval, without sacrificing the product quality or 






All the changes under SUPAC-SS refer to the initially approved composition or process and 
the possible impact on the in vivo performance. The level 2 changes are evaluated by 
adequately developed and validated IVR methodology. The topical semisolid products included 
in the TCS classes 1 and 3 also can be assimilated to one of these two levels of changes under 
SUPAC-SS. There is no scientific reason to believe that the assumed risks of the waiving 260 
procedures are higher in the approval of a generic topical semisolid product under the TCS 
principles, compared to the post-approval changed formulation under SUPAC-SS. SUPAC-SS 
guidance allows for a maximum 10% change in the quantity of any or collectively, all excipients, 
by applying IVR tests. The same principles are suggested to be implemented for TCS class 3 drug 
products. Any quantitative changes outside the previously mentioned ranges are to be analyzed 265 
for their in vivo significance. Only in cases where the lack of significant impact of safety and 
efficacy profiles is concluded, the  IVR (Q3) should be used as the basis of waiving the in vivo 
demonstration of bioequivalence. IVR (Q3) differences will indicate that alternative methods 
must be considered, as pointed out in the recently reported “Decision Tree Strawman for 
Determination of Topical Bioequivalence” (Yacobi et al., 2014). It is to be noted that the 270 
currently described TCS framework, based on Q1, Q2 and Q3 similarities, represents a 
particularization of the first tier of the decision tree. This classification system is based on the 
composition and characteristics of the topical semisolid dosage forms and uses the IVR 
methodology as a product qualifying tool, similar to SUPAC-SS. The difference resides on the 
extended applicability of IVR, beyond the current role of supportive, not surrogate 275 
methodology in the assessment of bioequivalence. 
 
8. CONCLUSION 
A practical and science based classification system, TCS, for topical drug products is 
proposed that will facilitate generic product development, reduce the regulatory burden and 280 
assure product quality. This will facilitate the development of topical generic products across all 
therapeutic classes, at all strengths at which the RLD is marketed, their approval, and ultimately 
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Figure 3: Topical Drug Classification System, TCS 
 360 
 
